On or around 03/25/2019 (Ongoing date of last review)
Filing Date: December 27, 2018
According to the Complaint, Immunomedics purports to be a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.
The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts.
Company & Securities Information
Defendant: Immunomedics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: IMMU
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Ahmad Odeh, et al. v. Immunomedics, Inc., et al.
COURT: D. New Jersey
DOCKET #: 18-CV-17645
JUDGE: Hon. Madeline Cox Arleo
DATE FILED: 12/27/2018
CLASS PERIOD START: 08/23/2018
CLASS PERIOD END: 12/20/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Block & Leviton LLP 155 Federal Street, Suite 1303, Block & Leviton LLP, MA 02110 (617) 398-5600 (617) 507-6020 ·